title: [Effect of FK506 eye-drop combined with keratoplasty on recurrent Mooren's ulcer].
abstract: OBJECTIVE
  To observe the effect of FK506 eye-drop combined with keratoplasty on recurrent Mooren's ulcer.
  
  
  METHODS
  9 cases (15 eyes) of recurrent Mooren's ulcer were treated with topical FK506 eye-drop combined with keratoplasty. Of the 15 eyes, two of Mooren's ulcer smaller than half circle of the limbus were treated with 0.1% FK506 eye-drop. Among the other 13 eyes of the ulcer larger than half the circle of the limbus, 12 eyes were treated with excision of conjunctiva combined with lamellar keratoplasty. One eye with a central corneal perforation was treated with penetrating keratoplasty. FK506 eye-drop 0.1% was given to the 13 operated eyes after the re-epithelialization of the cornea. The effect of FK506 on recurrent Mooren's ulcer was observed. Measurements of FK506 in surgically resected cornea and conjunctiva, and aqueous humor of the operated eyes were performed using enzyme immunoassay procedure. Twelve cases of recurrent Mooren's ulcer treated with lamellar keratoplasty combined with topical 0.1% dexamethasone eye-drop were taken as control.
  
  
  RESULTS
  After application of 0.1% FK506 eye-drop, concentrations of 30 - 350 ng/g of FK506 were found in the cornea and conjunctiva, and no FK506 was measured in the aqueous humor. Nine cases (15 eyes) of recurrent Mooren's ulcer were all cured and no recurrence was observed during the follow-up time of 12 - 17 months. The vision of 5 eyes was improved more than 2 lines after the treatment. Seven eyes of Mooren's ulcer in the control group recurred.
  
  
  CONCLUSIONS
  0.1% FK506 eye-drop combined with keratoplasty is an effective treatment for recurrent Mooren's ulcer.
authors.affiliation: Zhongshan Ophthalmic Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, China (Email: xiehanping@163.net)
authors.forename: Hanping
authors.initials: H
authors.lastname: Xie
authors.forename: Jiaqi
authors.initials: J
authors.lastname: Chen
authors.forename: Yuesheng
authors.initials: Y
authors.lastname: Lin
authors.forename: Yongmin
authors.initials: Y
authors.lastname: Liu
authors.forename: Chengtian
authors.initials: C
authors.lastname: Ye
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D003315:Cornea / Q000187:drug effects / Q000473:pathology; D016039:Corneal Transplantation / Q000379:methods*; D003320:Corneal Ulcer / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D016559:Tacrolimus